An observational study in Chronic Idiopathic Constipation (CIC), sponsored by Takeda. Active, not recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Takeda · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Constipation by Takeda — none open to participants now, 2 under way, none of them phase 3. Constipation · Takeda.
Among the 29 studies in Constipation by Takeda, this one is one of 2 that started in 2021, is one of 2 observational ones, and was the 28th registered.
1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.
Browse Constipation studies →None of the 29 studies in Constipation by Takeda is open now. The open studies under Constipation, anywhere →
Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is close to the median of 120 across 126 observational studies indexed under Constipation.
Median enrollment 211 across the 27 interventional studies, 113 across the 2 observational. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
2 of the studies in Constipation by Takeda that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04869280TakedaPost-Marketing Study of Prucalopride Safety In Pregnancy | 2027-02-01 |
| NCT04961840TakedaA Study to Assess Maternal and Fetal Outcomes After Taking Prucalopride During Pregnancy | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Constipation by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study collects information on pregnant women with ongoing constipation who took prucalopride and those who did not take prucalopride. The main aim of the study is to learn if any medical problems in pregnant women or their infants might be related to taking prucalopride during pregnancy.
Participants are not required to take prucalopride during the study. The study is non-interventional. Women and their infants are followed during pregnancy and for 1 year after pregnancy to collect information on maternal, pregnancy, and infant outcomes.
During the study, participants will be asked questions during 3 telephone interviews; 2 during pregnancy and 1 just after their expected delivery date. Participants who took or are taking prucalopride will be asked more detailed questions about this during these interviews. All information is collected remotely, and no visits to the study site are required.
Also, all participants will be asked to complete a questionnaire about their baby when their baby is about 1 year old.
Pregnant women from the United States (US) and Canada who have or have not been treated with prucalopride for CIC or IBS-C during their pregnancy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Cohort 1: Prucalopride-Exposed (MOTEGRITY, RESOTRAN) Cohort:
Cohort 2: Disease-Matched Comparison Cohort:
Exclusion Criteria:
Cohort 1: Prucalopride-Exposed (MOTEGRITY, RESOTRAN) Cohort
Cohort 2: Disease-Matched Comparison Cohort:
Pregnant women diagnosed with chronic idiopathic constipation (CIC) or irritable bowel syndrome-constipation (IBS-C) who have been exposed to prucalopride during pregnancy and prior to enrollment will be observed.
Other: No Intervention
Pregnant women diagnosed with CIC or IBS-C who have not been exposed to prucalopride will be observed.
Other: No Intervention
This is a non-interventional study.
Percentage of Participants With Major Structural Defects
Major structural defects are defined and classified using the US Centers for Disease Control and Prevention (CDC) coding manual that is used for the Metropolitan Atlanta Congenital Defects Program (MACDP) classification of major structural defects. All major structural defects will be adjudicated by the co-investigator on this study.
Time frame: Up to 1 year of age
Number of Participants With Spontaneous Abortion/Miscarriage
Spontaneous abortion/miscarriage is defined as non-deliberate fetal death that occurs prior to 20 weeks post-LMP.
Time frame: 20 weeks post-last menstrual period (LMP)
Number of Participants With Stillbirth
Stillbirth is defined as non-deliberate fetal death anytime in gestation at or after 20 weeks post-LMP.
Time frame: From 20 weeks post-LMP to end of pregnancy
Number of Participants With Elective Termination/Abortion
Elective termination/abortion is defined as deliberate termination of pregnancy through medication or surgical procedures. Elective abortions are classified for medical or social reasons.
Time frame: At the end of pregnancy or through 9-month pregnancy period
Number of Participants With Premature Delivery
Premature delivery is defined as live birth prior to 37 weeks gestation as counted from LMP (or calculated from first-trimester ultrasound-derived due date if LMP uncertain or more than 1 week discrepant). Elective caesarian deliveries or inductions prior to 37 completed weeks will be considered separately.
Time frame: Through 9-month pregnancy period
Incidence of Small for Gestational Age
Small for gestational age is defined as birth size (weight, length or head circumference) less than the 10th centile for sex and gestational age using standard pediatric CDC growth curves for full term or preterm infants.
Time frame: At birth
Number of Participants With Postnatal Growth Deficiency
Postnatal growth deficiency is defined as postnatal size (weight, length or head circumference) less than the 10th centile for sex and age using National Center for Health Statistics (NCHS) pediatric growth curves, and adjusted postnatal age for premature infants if the postnatal measurement is obtained at less than 1 year of age.
Time frame: Up to 1 year of age
Screening for Neurodevelopmental Milestones
Screening for neurodevelopment performed using the Ages and Stages Questionnaire (ASQ). An abnormal score is defined in the scoring guidelines.
Time frame: 1 year of age
Incidence of Hospitalization in Live Born Children
Hospitalizations is defined as any hospitalization of the infant within the first year of life after discharge following delivery.
Time frame: Up to 1 year of age
Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.
Started May 2021 (actual). Primary completion is estimated for Feb 2027, 68 months after the start.
Of 52 observational studies under Constipation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 46. This study's planned 68 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.